For Eileen McGill Fox, the collapse of a 30-year marriage brought a betrayal that extended far beyond emotional heartbreak. A Florida teacher and mother of four, Fox discovered her husband’s infidelity and immediately sought medical testing for sexually transmitted infections (STIs). When her initial results came back negative for HIV, syphilis, and gonorrhea, she felt a fleeting sense of relief, believing she had escaped the physical consequences of her partner’s actions.
That security proved illusory. Within a year, a routine cervical screening revealed she was positive for the Human Papillomavirus (HPV), a common but often silent virus. What followed was a grueling medical odyssey: Fox was eventually diagnosed with three distinct types of HPV-related cancers, a rare and devastating progression that she is now sharing publicly to dismantle the stigma surrounding STIs and urge a broader commitment to vaccination.
As a physician, I have seen how the “silent” nature of HPV often leads to missed opportunities for early intervention. Unlike many STIs that present with immediate, acute symptoms, high-risk strains of HPV can remain dormant for years, subtly altering cellular DNA until they manifest as malignancy. In Fox’s case, the virus didn’t just target one area. it triggered a cascade of oncogenic changes across multiple sites.
The progression from infection to triple diagnosis
The trajectory of Fox’s illness highlights the aggressive potential of certain HPV strains. Just two months after her initial HPV diagnosis, she was diagnosed with vulvar cancer. The medical challenge did not end there; in 2019, she was diagnosed with cervical cancer, and by 2023, she faced a third diagnosis: anal cancer.
The treatment process was exhaustive, requiring a hysterectomy and various other procedures to excise precancerous and malignant cells. Fox describes a profound sense of regret over not receiving the HPV vaccine when it first became available, noting that because she was already married at the time, she assumed the vaccine was unnecessary for her life stage.
| Year/Period | Medical Event/Diagnosis |
|---|---|
| Initial Discovery | Discovery of infidelity; Negative results for HIV, Syphilis, and Gonorrhea |
| One Year Later | HPV positive via annual cervical screening |
| Two Months Post-HPV | Diagnosis of Vulvar Cancer |
| 2019 | Diagnosis of Cervical Cancer |
| 2023 | Diagnosis of Anal Cancer |
The ‘silent’ nature of HPV and the testing gap
One of the most critical takeaways from Fox’s experience is the gap in standard STI screenings. Many patients assume a “full panel” covers everything, but HPV is typically detected through specific cervical screenings (like Pap smears or HPV DNA tests) rather than the standard urine or blood tests used for gonorrhea or chlamydia.
Susan Vadaparampil, a researcher at the Moffitt Cancer Center in Tampa, emphasizes that the public perception of the vaccine has often been too narrow. Vadaparampil notes that if the communication 20 years ago had clearly stated that the vaccine could prevent up to six different types of cancer, uptake likely would have been significantly higher.
The virus is notoriously stealthy. According to the National Health Service (NHS), most people with HPV will never develop symptoms or even know they are infected, as the immune system often clears the virus on its own. However, when the virus persists, it can lead to the types of malignancies Fox experienced.
Dismantling the stigma of sexual health
Beyond the clinical battle, Fox is fighting a social one. She is calling for an end to the shame and stigma associated with HPV, pointing out that her status as a long-term married woman and mother proves that anyone can be affected. The stigma often prevents people from seeking testing or encourages partners to hide infidelity, which in turn delays life-saving diagnoses.
The efficacy of preventative measures is well-documented. In the United Kingdom, where the HPV vaccine was introduced for girls in 2008 and expanded to boys in 2019, the results have been transformative. Research published in The Lancet indicates that cervical cancer rates have dropped by nearly 90% among women who were vaccinated between the ages of 12, and 13.
Key preventative takeaways for adults:
- Routine Screening: Regular Pap tests and HPV screenings are essential for early detection, even for those in monogamous relationships.
- Vaccination: While primarily targeted at adolescents, the vaccine is available for adults. Consult a provider to see if you are still a candidate.
- Open Communication: Honest discussions about sexual health history can prompt necessary testing that might otherwise be overlooked.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for diagnosis, treatment, and vaccination guidance.
As public health initiatives continue to expand vaccine access to both genders and older age groups, the goal is to move toward a future where HPV-related cancers are a rarity rather than a tragedy. The next major milestone in global efforts is the WHO’s strategy to eliminate cervical cancer as a public health problem by 2030, focusing on 90% vaccination coverage for girls by age 15.
We invite you to share your thoughts or experiences with preventative health screenings in the comments below.
